Mental DailyMental Daily
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • The Discussion
    • My Bookmarks
Aa
Mental Daily
Aa
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • Opinion
Search
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • The Discussion
    • My Bookmarks
Follow US
  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store
© 2022 - Mental Daily. All Rights Reserved.
Health

Sputnik V is highly effective for the prevention of COVID-19 contagion

Staff Writer
Staff Writer 1 year ago
Updated 2021/05/12 at 6:20 PM
Share
SHARE

In the midst of the COVID-19 pandemic, the Gam-COVID-Vac (Sputnik V), developed by the Gamaleya Research Institute of Epidemiology and Microbiology, has demonstrated to be highly effective in preventing contagion, according to new clinical data.

As published in the peer-reviewed journal the Lancet, Phase III trial data involving nearly 20,000 participants yielded an overall efficacy rate above 91 percent. Clinicians claim the vaccine could be up to 100 percent effective at preventing infection.

Among the elderly, the efficacy rate is also above 91 percent, a much higher rate in comparison to nearly all other competing Western-made vaccines for this age group.

“A heterologous recombinant adenovirus (rAd)-based vaccine, Gam-COVID-Vac (Sputnik V), showed a good safety profile and induced strong humoral and cellular immune responses in participants in phase 1/2 clinical trials,” the Lancet findings state.

“Here, we report preliminary results on the efficacy and safety of Gam-COVID-Vac from the interim analysis of this phase 3 trial.”

Sputnik V was touted as such a success that other pharmaceutical giants working on their own vaccine, including one led by Oxford University, had experimented on combining with Russia’s creation to boost efficacy.

As of Q1 2021, Western vaccines from Pfizer-BioNTech, Moderna, and Lilly, have been the only efficacious ones approved to take on the COVID-19 pandemic. Indian and Chinese vaccinations have also been approved to combat the virus for their populants, however, its clinical trial data remains scarce.

In January 2021, Merck discontinued the development of its vaccine. Oxford’s creation, also developed by AstraZeneca, has shown to be ineffective for many adults, particularly the elderly, and possibly for those of younger age. Researchers at Oxford have reportedly engaged in medical misinformation during the height of the pandemic, as clinical data estimates about 60 percent efficacy rate after two doses of their anti-viral vaccine.

With Sputnik V having been distributed throughout the Russian Federation, other nations in Latin America, Africa, the Middle East, Asia, and Europe have already received Russia’s breakthrough vaccine.

Sputnik V, though, has yet to be approved in North America.

Photo: Dmitry Kurakin/Russia's Health Ministry

You Might Also Like

New research claims COVID-19 contagion may raise the risk of neurodegenerative disorder

New research of vegetarian diets uncovered similar growth and nutrition as meat consumers

Being overweight during childhood may raise the risk of type 1 diabetes

Over a million less smokers projected after U.S. ban on menthol cigarettes: study

Study probes the communication between physicians and patients regarding e-cigarette use

TAGGED: COVID-19, epidemiology, Sputnik V
Staff Writer February 2, 2021
Share this Article
Facebook Twitter Whatsapp Whatsapp Email Print
Previous Article Exposure to air pollution may be linked to deterioration in cognitive skills
Next Article Researchers examine the state of maternal mental health during COVID-19 lockdowns

Recommended

Clinical

New research claims COVID-19 contagion may raise the risk of neurodegenerative disorder

1 Min Read
Health

New research of vegetarian diets uncovered similar growth and nutrition as meat consumers

1 Min Read
Health

Being overweight during childhood may raise the risk of type 1 diabetes

1 Min Read
Health

Over a million less smokers projected after U.S. ban on menthol cigarettes: study

1 Min Read
//

We are a trusted online source for research news and resources on all aspects of the mind and human behavior.

Verticals

  • Clinical
  • Health
  • Social
  • I/O
  • Opinion

Social

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Links

  • About
  • Contact
  • Terms & Conditions
  • Privacy Policy
Follow US

© 2022 Mental Daily. All Rights Reserved.

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?